Nitrogen Attached Indirectly To The Hetero Ring By Nonionic Bonding Patents (Class 549/491)
  • Patent number: 10829441
    Abstract: Disclosed are ROS-sensitive NOS inhibitors, as well as methods of making and using the same.
    Type: Grant
    Filed: October 31, 2018
    Date of Patent: November 10, 2020
    Assignee: The University of Toledo
    Inventors: Kevin M. Nash, Isaac Schiefer, Zahoor Shah
  • Patent number: 10364210
    Abstract: Provided herein are (phenylene)dialkanamines, and methods of producing such (phenylene)dialkanamines from various furanyl and benzyl compounds. Such furanyl compounds may include, for example, bis(nitroalkyl)furans, bis(aminoalkyl)furans, and nitroalkyl(furan)acetonitriles. Such compounds may include, for example, bis(nitroalkyl)benzenes. Provided herein are also alkyldiamines, and methods for producing such alkyldiamines from furanyl compounds.
    Type: Grant
    Filed: August 27, 2015
    Date of Patent: July 30, 2019
    Assignee: MICROMIDAS, INC.
    Inventors: Alex B. Wood, Makoto Nathanael Masuno, Ryan L. Smith, John Albert Bissell, II, Robert Joseph Araiza, Dimitri A. Hirsch-Weil
  • Patent number: 10188627
    Abstract: Provided herein are compounds of formula (I) useful for the treatment of PPAR-delta related diseases (e.g. mitochondrial diseases, muscular diseases, vascular diseases, demyelinating diseases and metabolic diseases).
    Type: Grant
    Filed: October 7, 2015
    Date of Patent: January 29, 2019
    Assignees: Mitobridge, Inc., Salk Institute for Biological Studies
    Inventors: Michael Downes, Ronald Evans, Arthur Kluge, Bharat Lagu, Masanori Miura, Sunil Kumar Panigrahi, Michael Patane, Susanta Samajdar, Ramesh Senaiar, Taisuke Takahashi
  • Publication number: 20150126511
    Abstract: The invention relates to novel cyclohexylamine derivatives and their use in the treatment and/or prevention of central nervous system (CNS) disorders, such as depression, anxiety, schizophrenia and sleep disorder as well as methods for their synthesis. The invention also relates to pharmaceutical compositions containing the compounds of the invention, as well as methods of inhibiting reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine from the synaptic cleft and methods of modulating one or more monoamine transporter.
    Type: Application
    Filed: September 30, 2014
    Publication date: May 7, 2015
    Inventors: Liming SHAO, Fengjiang WANG, Scott Christopher MALCOLM, Michael Charles HEWITT, Larry R. BUSH, Jianguo MA, Mark A. VARNEY, Una CAMPBELL, Sharon Rae ENGEL, Larry Wendell HARDY, Patrick KOCH, John E. CAMPBELL
  • Publication number: 20150080369
    Abstract: The present invention is directed to novel retinoid-related orphan receptor gamma (ROR?) modulators, processes for their preparation, pharmaceutical compositions containing these modulators, and their use in the treatment of inflammatory, metabolic and autoimmune diseases mediated by ROR?.
    Type: Application
    Filed: April 25, 2013
    Publication date: March 19, 2015
    Inventors: Veronique Birault, Amanda Jennifer Campbell, Stephen Harrison, Joelle Le, Lena Shukla
  • Patent number: 8962865
    Abstract: A process is disclosed for the preparation of a compound of formula and/or an addition salt of a proton acid, wherein R1 and R2 independently represent alkyl, cycloalkyl, aryl or aralkyl, each aryl or aralkyl being optionally further substituted with alkyl, alkoxy and/or halogen.
    Type: Grant
    Filed: July 25, 2013
    Date of Patent: February 24, 2015
    Assignee: Lonza AG
    Inventors: Dominique Michel, Rudolf Fuchs
  • Patent number: 8952094
    Abstract: A composition includes a reversible polymer material, which can reversibly transition between a liquid state and a solid state by reversible cycloaddition reactions, wherein upon cooling, the reversible polymer material transitions from a liquid state to a solid state by reversible cycloaddition reactions within a time period of less than about 10 seconds.
    Type: Grant
    Filed: May 30, 2013
    Date of Patent: February 10, 2015
    Assignee: Xerox Corporation
    Inventors: James D. Mayo, Stephan Drappel, C. Geoffrey Allen, Biby E. Abraham, Sonja Hadzidedic
  • Patent number: 8927586
    Abstract: The present invention relates to novel TP receptor antagonists, which optionally cross the blood-brain barrier of a mammal. The invention also provides methods for treating a disorder related to activation of TP receptor utilizing the compounds of the invention.
    Type: Grant
    Filed: February 28, 2013
    Date of Patent: January 6, 2015
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: John Q. Trojanowski, Virginia M. Y. Lee, Kurt R. Brunden, Amos B. Smith, Donna M. Huym, Carlo Ballatore, Anne-Marie Hogan, Francesco Piscitelli, Sugiyama Shimpei, Xiaozhao Wang
  • Publication number: 20140341986
    Abstract: Provided herein are methods for treating certain conditions, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administrating a composition comprising a biguanide or related heterocyclic compound, e.g., metformin. Also provided herein are biguanide or related heterocyclic compound compositions, and methods for the preparation thereof for use in the methods of the present invention. Also provided herein are compositions comprising metformin and salts thereof and methods of use.
    Type: Application
    Filed: August 4, 2014
    Publication date: November 20, 2014
    Inventors: Alain D. Baron, Mark S. Fineman, Nigel R.A. Beeley
  • Patent number: 8883180
    Abstract: The invention relates to active compound combinations, in particular a fungicidal and/or insecticidal composition, comprising Isotianil (3,4-dichloro-N-(2-cyanophenyl)-5-isothiazolecarboxamide) and at least one further insecticide of the anthranilamide group and optionally one further insecticide of the neonicotinoids. Moreover, the invention relates to a method for curatively or preventively controlling the phytopathogenic fungi and/or microorganisms and/or pests of plants or crops, to the use of a combination according to the invention for the treatment of seed, to a method for protecting a seed and not at least to the treated seed.
    Type: Grant
    Filed: August 29, 2013
    Date of Patent: November 11, 2014
    Assignee: Bayer Intellectual Property GmbH
    Inventors: Lutz Assmann, Ulrike Wachendorff-Neumann, Peter Dahmen, Heike Hungenberg, Wolfgang Thielert
  • Publication number: 20140323501
    Abstract: Immune-modulators of formula (I) below are prepared: A pharmaceutical composition contains the immune-modulators. The pharmaceutical composition is used as a drug, especially as an immune-modulating drug. The compound can be used in treatment of immune disorders and for immune suppression. Thus, for example, the compound can be used in treating hypo-immunity, rejection after organ transplantation and auto-immune disease.
    Type: Application
    Filed: July 5, 2012
    Publication date: October 30, 2014
    Applicant: INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES
    Inventors: Weijuan Han, Haijing Zhang, Xiaojian Wang, Jing Jin, Gang Li, Yi Zhang, Qiong Xiao, Wanqi Zhou, Xiaoguang Chen, Dali Yin
  • Publication number: 20140315898
    Abstract: The present invention relates to novel N-arylamide-substituted trifluoroethyl sulfide derivatives of the formula (I) in which X1, X2, X3, X4, R1, R2, R3, n have the meanings given in the description—to their use as acaricides and insecticides for controlling animal pests and to processes and intermediates for their preparation
    Type: Application
    Filed: December 12, 2012
    Publication date: October 23, 2014
    Applicant: BAYER CROPSCIENCE AG
    Inventors: Adeline Koehler, Bernd Alig, Angela Becker, Arnd Voerste, Ulrich Goergens, Reiner Fischer, Wahed Ahmed Moradi, Silvia Cerezo-Galvez, Julia Johanna Hahn, Kerstin Ilg, Hans-Georg Schwarz, Takuya Gomibuchi, Masahito Ito, Daiei Yamazaki, Katsuhiko Shibuya, Eiichi Shimojo
  • Publication number: 20140275043
    Abstract: The present invention relates generally to compositions and methods for treating neurodegenerative diseases and disorders, particularly ophthalmic diseases and disorders. Provided herein are substituted 3-phenylpropylamine derivative compounds and pharmaceutical compositions comprising said compounds. The subject compositions are useful for treating and preventing ophthalmic diseases and disorders, including age-related macular degeneration (AMD) and Stargardt's Disease.
    Type: Application
    Filed: March 11, 2014
    Publication date: September 18, 2014
    Applicant: Acucela Inc.
    Inventors: Vladimir A. Kuksa, Mark W. Orme, Feng Hong, Ryo Kubota
  • Publication number: 20140275582
    Abstract: Provided herein are novel chiral sulfinamide and imine compounds. Also provided herein are methods of synthesizing novel chiral sulfinamide and imine compounds comprising simplified purification methods when compared to prior methods. The novel chiral sulfinamide and imine compounds are useful, for example, in the synthesis of complex natural products and pharmaceutical important compounds.
    Type: Application
    Filed: March 12, 2014
    Publication date: September 18, 2014
    Applicants: Texas Tech University, Nanjing University, Institute of Chemistry and Biomedical Sciences
    Inventor: Guigen LI
  • Publication number: 20140235533
    Abstract: The present invention provides compounds of formula I wherein Q is Q1 or Q2; A1, A2, A3 and A4 are independently of each other C—H, C—R7, or nitrogen; R1 is C1-C8haloalkyl; R2 is aryl or aryl substituted by one to five R11, or heteroaryl or heteroaryl substituted by one to five R11; and R3, R4, R5, R6 and R7 are as defined in the claims. The invention also provides methods of controlling insects, acarines, nematodes or molluscs which methods comprise applying to a pest, to a locus of a pest, or to a plant susceptible to attack by a pest an insecticidally, acaricidally, nematicidally or molluscicidally effective amount of a compound of formula (I).
    Type: Application
    Filed: August 10, 2012
    Publication date: August 21, 2014
    Applicant: SYNGENTA PARTICIPATIONS AG
    Inventors: Tomas Smejkai, Sebastian Volker Wendeborn, Jerome Yves Cassayre, Myriem El Qacemi, Bernhard Breit, Lisa Diab, Regis Jean Georges Mondiere
  • Patent number: 8716500
    Abstract: The present invention provides a method that allows production of stereospecific and asymmetrical five-membered ring-containing compounds serving as synthetic intermediates for formation of five-membered rings of prostaglandins and the like, with high yield and excellent stereoselectivity in terms of diastereoselectivity and enantioselectivity in a short process without requiring troublesome procedures such as optical resolution.
    Type: Grant
    Filed: April 27, 2012
    Date of Patent: May 6, 2014
    Assignee: Ono Pharmaceutical Co., Ltd.
    Inventor: Yujiro Hayashi
  • Publication number: 20140100371
    Abstract: A process for preparing azomethines of the general formula (V) where R is an optionally substituted carbocyclic aromatic radical having 6 to 24 carbon atoms or an optionally substituted alkyl radical or an optionally substituted heteroaromatic radical having 5 to 24 carbon atoms, and R1 is an optionally substituted carbocyclic aromatic radical having 6 to 24 carbon atoms or an optionally substituted heteroaromatic radical having 5 to 24 carbon atoms, R2 is hydrogen or an optionally substituted carbocyclic aromatic radical having 6 to 24 carbon atoms or an optionally substituted alkyl radical or an optionally substituted cycloalkyl radical N or an optionally substituted heteroaromatic radical having 5 to 24 carbon atoms by reacting alpha-oxo carboxylates of the general formula (I) where n is a number in the range from 1 to 6, M(n+) is a cation, with aryl bromides of the general formula (IV) and amines of the general formula (II) via the alpha-iminocarboxylate intermediate of the general formula (III), in the p
    Type: Application
    Filed: November 18, 2011
    Publication date: April 10, 2014
    Applicant: Saltigo GmbH
    Inventors: Alain Cotte, Matthias Cotta, Felix Rudolph, Bingrui Song, Lukas Goossen
  • Patent number: 8669383
    Abstract: Described herein are single step methods of making various classes of alkylamine derivatives of furan and tetrahydrofuran by simultaneous contact of a sugar with H2, an acid catalyst and hydrogenation catalyst in the presence of an alkylamide solvent. The hydrogenation catalyst is a heterogeneous catalyst comprising a metal selected from the group consisting of Pt, Pd, and nickel. The acid catalysts may be homogeneous mineral acid or a heterogeneous acid catalyst on substrate. In a preferred practice the two catalysts are provided on a common heterogeneous bifunctional support. Using similar combinations of acid and hydrogenation catalysts, there is also described single step methods for making furandimethanol by simultaneously contacting a hexose with the two separate catalysts in the presence of H2 in an aprotic solvent, such as dimethylformamide.
    Type: Grant
    Filed: December 13, 2011
    Date of Patent: March 11, 2014
    Assignee: Archer Daniels Midland Company
    Inventors: Stephen Howard, Alexandra Sanborn
  • Publication number: 20140051874
    Abstract: The present invention provides a method that allows production of stereospecific and asymmetrical five-membered ring-containing compounds serving as synthetic intermediates for formation of five-membered rings of prostaglandins and the like, with high yield and excellent stereoselectivity in terms of diastereoselectivity and enantioselectivity in a short process without requiring troublesome procedures such as optical resolution.
    Type: Application
    Filed: April 27, 2012
    Publication date: February 20, 2014
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventor: Yujiro Hayashi
  • Patent number: 8653286
    Abstract: Methods for forming maleimide functionalized polymers are provided. In one such embodiment, a maleimide functionalized polymer is prepared in a method that includes a step of carrying out a reverse Diels-Alder reaction. Intermediates useful in the methods, as well as methods for preparing the intermediates, are also provided. Also provided are polymeric reagents, methods of using polymeric reagents, compounds and conjugates.
    Type: Grant
    Filed: August 7, 2012
    Date of Patent: February 18, 2014
    Assignee: Nektar Therapeutics
    Inventors: Samuel P. McManus, Antoni Kozlowski, Tracy L. Hutchison, Brian Bray, Xiaoming Shen
  • Patent number: 8614010
    Abstract: Provided are an organic electroluminescence device that not only provides high efficiency but also has a long lifetime, and an aromatic amine derivative that realizes the device. The organic electroluminescence device includes an aromatic amine derivative, including at least one substituent A having dibenzofuran and at least one substituent B selected from groups each having dibenzofuran or carbazole, in a molecule thereof, in which the substituent A and the substituent B include groups different from each other, and the substituent A and the substituent B are bonded to the same nitrogen atom, or different nitrogen atoms, in the molecule. The molecules of the aromatic amine derivative hardly crystallize, which improves a yield in the production of the organic electroluminescence device.
    Type: Grant
    Filed: November 24, 2009
    Date of Patent: December 24, 2013
    Assignee: Idemitsu Kosan, Co., Ltd.
    Inventors: Nobuhiro Yabunouchi, Masahiro Kawamura, Tomoki Kato
  • Publication number: 20130281462
    Abstract: Disclosed herein are compounds (for example, diamidine derivatives and prodrugs) and methods of use thereof, for example in treating muscular dystrophy (DM) or disease caused by a toxic RNA in a subject. In some embodiments, the methods include administering an effective amount of one of more of the disclosed compounds to a subject to treat or inhibit DM or a disease caused by or associated with toxic RNA, such as DM1, DM2, spinocerebellar ataxia type 8 (SCA8), fragile X tremor ataxia syndrome (FXTAS), or Huntington disease-like 2 (HLD2). In some examples, the methods include selecting a subject for treatment, for example selecting a subject with DM1, DM2, SCA8, FXTAS, or HLD2.
    Type: Application
    Filed: April 19, 2013
    Publication date: October 24, 2013
    Applicants: University of Oregon
    Inventor: State of Oregon, acting by and through the State Board of Higher Education, on behalf of the University of Oregon
  • Publication number: 20130274283
    Abstract: Premature termination codons readthrough compounds, composition thereof, and methods of making and using the same are provided.
    Type: Application
    Filed: February 11, 2013
    Publication date: October 17, 2013
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Richard A. GATTI, Liutao DU, Robert DAMOISEAUX, Chih-Hung LAI, Michael JUNG, Jin-Mo KU, Carmen BERTONI
  • Publication number: 20130252964
    Abstract: The present disclosure provides compounds, or pharmaceutically acceptable salts thereof, for killing or inhibiting the growth of a Candida or Aspergillus species or preventing or treating a mammal having candidiasis (oral and/or disseminated) or an Aspergillus infection.
    Type: Application
    Filed: January 18, 2013
    Publication date: September 26, 2013
    Applicant: PolyMedix, Inc.
    Inventors: Richard W. Scott, Katie Freeman, Haizhong Tang, Gill Diamond
  • Patent number: 8513162
    Abstract: There is provided a halogen-containing organosulfur compound having a controlling effect on arthropod pests represented by the formula (I): wherein m represents 0, 1 or 2; n represents 0, 1 or 2; A represents an optionally substituted 3- to 8-membered saturated heterocyclic group; Q represents a fluorine atom or a C1-C5 haloalkyl group having at least one fluorine atom; R1, R1a and R3 independently represent an optionally halogenated C1-C4 chain hydrocarbon group, etc.; R2, R2a and R4 independently represent an optionally halogenated C1-C4 chain hydrocarbon group, etc.
    Type: Grant
    Filed: December 24, 2009
    Date of Patent: August 20, 2013
    Assignee: Sumitomo Chemical Company, Limited
    Inventor: Hiromasa Mitsudera
  • Publication number: 20130190370
    Abstract: The present invention relates to TP receptor antagonists, which have the ability to bind to TP receptor and optionally cross the blood brain barrier. The invention also provides compositions and methods for treating a disorder wherein activation of TP receptor is detrimental.
    Type: Application
    Filed: July 27, 2011
    Publication date: July 25, 2013
    Applicant: The Trustees of the University of Pennsylvania
    Inventors: John Q. Trojanowski, Virginia M.Y. Lee, Kurt R. Brunden, Amos B. Smith, Donna M. Huryn, Carlo Ballatore, Anne-Marie Hogan, Francesco Piscitelli
  • Publication number: 20130109713
    Abstract: The invention provides a compound of formula I:or a salt thereof, wherein R3-R8 and X and Y have any of the values described in the specification, as well as compositions comprising a compound of formula I. The compounds are useful as antibacterial agents.
    Type: Application
    Filed: June 24, 2011
    Publication date: May 2, 2013
    Inventors: Edmond J. Lavoie, Ajit Parhi, Daniel S. Pilch
  • Publication number: 20130095140
    Abstract: Provided herein are methods for treating certain conditions, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administrating a composition comprising a biguanide or related heterocyclic compound, e.g., metformin. Also provided herein are biguanide or related heterocyclic compound compositions, and methods for the preparation thereof for use in the methods of the present invention. Also provided herein are compositions comprising metformin and salts thereof and methods of use.
    Type: Application
    Filed: July 11, 2012
    Publication date: April 18, 2013
    Applicant: Elcelyx Therapeutics, Inc.
    Inventors: Alain D. Baron, Mark S. Fineman, Nigel R. A. Beeley
  • Patent number: 8357710
    Abstract: There is provided a compound of formula I, wherein R1a, R1b, X, Y1, Y2, Y3, Y4, Z1, Z2, R2 and R3 have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful as selective agonists of the AT2 receptor, and thus, in particular, in the treatment of inter alia gastrointestinal conditions, such as dyspepsia, IBS and MOF, and cardiovascular disorders.
    Type: Grant
    Filed: April 12, 2006
    Date of Patent: January 22, 2013
    Assignee: Vicore Pharma AB
    Inventors: Mathias Alterman, Anders Hallberg, Murugaiah Andappan Murugaiah Subbaiah
  • Publication number: 20120270902
    Abstract: The invention provides N-substituted benzenesulfonamides for use in treating or preventing cognitive disorders, such as Alzheimer's Disease. Compounds of particular interest are defined by Formula (I), wherein R1, R2, R3, R4, and R3?, are as described in the specification. The invention also encompasses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of treating cognitive disorders, including Alzheimer's disease using compounds of Formula (I).
    Type: Application
    Filed: February 13, 2012
    Publication date: October 25, 2012
    Applicant: ELAN PHARMACEUTICALS, INC.
    Inventors: Martin Neitzel, Jennifer Marugg
  • Patent number: 8258324
    Abstract: Methods for forming maleimide functionalized polymers are provided. In one such embodiment, a maleimide functionalized polymer is prepared in a method that includes a step of carrying out a reverse Diels-Alder reaction. Intermediates useful in the methods, as well as methods for preparing the intermediates, are also provided. Also provided are polymeric reagents, methods of using polymeric reagents, compounds and conjugates.
    Type: Grant
    Filed: September 15, 2011
    Date of Patent: September 4, 2012
    Assignee: Nektar Therapeutics
    Inventors: Samuel P. McManus, Antoni Kozlowski, Tracy L. Hutchison, Brian Bray, Xiaoming Shen
  • Publication number: 20120220590
    Abstract: Compounds of formula (I) and pharmaceutical compositions containing them are described. The use of the compounds and compositions are also described.
    Type: Application
    Filed: July 30, 2010
    Publication date: August 30, 2012
    Inventors: Pravin S. Thombare, Amitgiri Goswami, Edouard Zamaratski, Tomas Hansson, Thomas Norin
  • Publication number: 20120201958
    Abstract: The present invention is a plurality of metal-containing complexes of a multidentate ketoiminate.
    Type: Application
    Filed: July 21, 2011
    Publication date: August 9, 2012
    Applicant: Air Products and Chemicals, Inc.
    Inventors: Xinjian Lei, Daniel P. Spence
  • Patent number: 8236972
    Abstract: The instant invention involves a process for enhancing molecular mass of biomass reactants. The process comprises first forming a substituted or unsubstituted furfural from a biomass. The substituted or unsubstituted furfural is then reacted with an activated methylene compound in the presence of a catalyst and, if desired, a solvent to form a Knoevenagel product. The product may then be hydrogenated to products containing an alcohol, ether, aldehyde, or ketone functional groups or to an olefinic or aliphatic species wherein as much as all of the oxygen and/or nitrogen has been removed.
    Type: Grant
    Filed: July 29, 2008
    Date of Patent: August 7, 2012
    Assignee: Georgia Tech Research Corporation
    Inventors: Travis J. C. Hoskins, Carsten Sievers, Pradeep K. Agrawal, Christopher W. Jones
  • Publication number: 20120149693
    Abstract: The invention relates to protein binding interacting/binding compounds and methods of identifying and using them. The invention further relates to pharmaceutical compositions and methods for treating 5-HT2C and/or RSK disorders, including diseases and disorders mediated by GPCRs and/or RSKs.
    Type: Application
    Filed: May 5, 2010
    Publication date: June 14, 2012
    Applicant: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.
    Inventor: Raymond G. Booth
  • Publication number: 20120095024
    Abstract: The present invention provides novel compounds that inhibit cell proliferation and cell division and that inhibit the activation of Hypoxia Inducible Factor (HIF)-mediated transcription and signaling under hypoxic conditions. In one aspect, the compounds of the present invention are useful for the preparation of a medicament for the treatment or prevention of a disease or disorder selected from the group consisting of an inflammatory disease, a hyperproliferative disease or disorder, a hypoxia-related pathology and a disease characterized by excessive vascularisation. Also provided is a pharmaceutical composition comprising a compound of the invention and a second therapeutic agent or radiation useful for the treatment or prevention of the mentioned diseases or disorders. In a first aspect the present invention relates to a compound having a structure according to formula (I).
    Type: Application
    Filed: December 30, 2009
    Publication date: April 19, 2012
    Applicants: Elara Pharmaceuticals GmbH, European Molecular Biology Laboratory (EMBL)
    Inventors: Jorge Alonson, Arantxa Encionas Lopez, Marcel Muelbaler, Lochen Ammenn, Bernd Vendt, Joe Lewis, Christoph Schultes, Bernd Janssen
  • Publication number: 20120004225
    Abstract: The present invention provides bumetanide, furosemide, piretanide, azosemide, and torsemide analogs and compositions comprising such analogs. The present invention also provides pharmaceutical compositions containing these bumetanide, furosemide, piretanide, azosemide, and torsemide analogs and methods for their use. All of these analogs are particularly useful for the treatment and/or prophylaxis of conditions that involve the Na+K+Cl? co-transporter or GABAA receptor including but not limited to addictive disorders, Alzheimer's Disease, anxiety disorders, ascites, autism, bipolar disorder, cancer, depression, endothelial corneal dystrophy, edema, epilepsy, glaucoma, Huntington's Disease, insomnia, ischemia, migraine, migraine with aura, neuropathic pain, nociceptive neuralgia, nociceptive pain, ocular diseases, pain, Parkinson's disease, personality disorders, postherpetic neuralgia, psychosis, schizophrenia, seizure disorders, tinnitus, and withdrawal syndromes.
    Type: Application
    Filed: January 22, 2010
    Publication date: January 5, 2012
    Applicant: NeuroTherapeutics Pharma, Inc.
    Inventors: Stephen Wanaski, John J. Partridge, Stephen D. Collins
  • Patent number: 8044222
    Abstract: The present invention provides a novel aromatic amine derivative having a specific structure and an organic electroluminescence device in which an organic thin film layer comprising a single layer or plural layers including at least a light emitting layer is interposed between a cathode and an anode, wherein at least one layer in the above organic thin film layer, particularly a hole transporting layer contains the aromatic amine derivative described above in the form of a single component or a mixed component. Use of the aromatic amine derivative described above materialize an organic electroluminescence device which reduces an operating voltage and makes molecules less liable to be crystallized and which enhances a yield in producing the organic EL device and has a long lifetime.
    Type: Grant
    Filed: August 6, 2007
    Date of Patent: October 25, 2011
    Assignee: Idemitsu Kosan Co., Ltd.
    Inventors: Nobuhiro Yabunouchi, Masahiro Kawamura, Hisayuki Kawamura
  • Publication number: 20110257226
    Abstract: There is provided a halogen-containing organosulfur compound having a controlling effect on arthropod pests represented by the formula (I): wherein m represents 0, 1 or 2; n represents 0, 1 or 2; A represents an optionally substituted 3- to 8-membered saturated heterocyclic group; Q represents a fluorine atom or a C1-C5 haloalkyl group having at least one fluorine atom; R1, R1a and R3 independently represent an optionally halogenated C1-C4 chain hydrocarbon group, etc.; R2, R2a and R4 independently represent an optionally halogenated C1-C4 chain hydrocarbon group, etc.
    Type: Application
    Filed: December 24, 2009
    Publication date: October 20, 2011
    Inventor: Hiromasa Mitsudera
  • Publication number: 20110251196
    Abstract: The present disclosure is generally directed to compounds which can modulate G-protein coupled receptor 88, compositions comprising such compounds, and methods for modulating G-protein coupled receptor 88.
    Type: Application
    Filed: October 5, 2010
    Publication date: October 13, 2011
    Inventors: Carolyn Diane Dzierba, Richard A. Hartz, Yingzhi Bi, Vijay T. Ahuja, Joanne J. Bronson, Kenneth Carson, Giovanni Cianchetta, Michael Green, David Kimball, S. Roy Kimura, Soojin Kwon, John E. Macor, Yulian Zhang, Greg Zipp
  • Patent number: 8017558
    Abstract: Novel carboxamides of the formula (I) The present application is further directed toward a plurality of processes for preparing these compounds and their use for controlling unwanted microorganisms, and also novel intermediates and their preparation.
    Type: Grant
    Filed: December 5, 2006
    Date of Patent: September 13, 2011
    Assignee: Bayer Cropscience AG
    Inventors: Ralf Dunkel, Hans-Ludwig Elbe, Jörg Nico Greul, Herbert Gayer, Bernd-Wieland Krüger, Arnd Voerste, Ulrike Wachendorff-Neumann, Peter Dahmen
  • Patent number: 8013187
    Abstract: 2-cyclopenten-1-one oxime derivatives represented by Formula (I), or pharmaceutically acceptable salts thereof inhibit the production of TNF-? or PDE4, and therefore show therapeutic effect in inflammatory or immunological disorders mediated through TNF-? or PDE4.
    Type: Grant
    Filed: November 30, 2005
    Date of Patent: September 6, 2011
    Assignee: Amorepacific Corporation
    Inventors: Yeonjoon Kim, Sun-Young Kim, Jung Sun Hwang, Kyoung Min Lim, Miyoung Park, Hyun Ju Koh, Sa-Yong Hong, Song Seok Shin, Jin Kyu Choi, Joo-Hyun Moh, Shin Chung, Byoung Young Woo, Sung Il Kim
  • Patent number: 7989497
    Abstract: The present invention relates to compounds of formula (I) wherein X, R1, R2, R3, R4 and R5 are as defined herein, which are useful for treating diseases which respond to CXCR2 receptor mediators. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.
    Type: Grant
    Filed: July 30, 2009
    Date of Patent: August 2, 2011
    Assignee: Novartis AG
    Inventors: Urs Baettig, Anne-Marie D'Souza, Peter Hunt, Neil John Press, Simon James Watson
  • Patent number: 7977496
    Abstract: Disclosed is an improved process for producing nitroguanidine derivatives represented by the formula (3), which has an insecticidal activity, or a salt thereof, wherein the substituents are defined herein, in which nitroisourea derivatives represented by the following general formula (1) or a salt thereof wherein the substituents are defined herein, and compounds represented by the following general formula (2) or a salt thereof, wherein the substituents are defined herein, are reacted in the presence of a base in an aqueous solution wherein an inorganic salt is dissolved at not less than 50% of its saturated solubility.
    Type: Grant
    Filed: February 7, 2007
    Date of Patent: July 12, 2011
    Assignee: Mitsui Chemicals, Inc.
    Inventors: Hisato Kamekawa, Tomotaka Miyashita, Hiroyuki Katsuta, Toshio Kitashima
  • Patent number: 7977332
    Abstract: Certain noel N-(heteroarylalkyl)alkanediamine derivatives have provided unexpected insecticidal and acaricidal activity. These compounds are represented by formula I: wherein Ar, a, r, R, Ra, Rb, Rc, Rd, b, c, Re, Rf, Rg, Rh, R5, d, e, U, V, X, WR6 and R7 are fully described herein. In addition, compositions comprising an insecticidally effective amount of at least one compound of formula I, and optionally, an effective amount of at least one of a second compound, with at least one insecticidally compatible carrier are also disclosed; along with methods of controlling insects comprising applying said compositions to a locus where insects are present or are expected to be present.
    Type: Grant
    Filed: December 2, 2004
    Date of Patent: July 12, 2011
    Assignee: FMC Corporation
    Inventors: David M. Roush, John F. Chiarello, Jianming Yu, Benjamin J. Dugan, George Theodoridis, Manorama M. Patel, Walter H. Yeager, Steven W. Szczepanski
  • Publication number: 20110165188
    Abstract: The present invention is directed to N-hydroxyamidino compounds which are modulators of indoleamine 2,3-dioxygenase (IDO), as well as compositions and pharmaceutical methods thereof.
    Type: Application
    Filed: March 17, 2011
    Publication date: July 7, 2011
    Inventors: Andrew P. Combs, Brian M. Glass, Richard B. Sparks, Eddy Way Tsun Yue
  • Publication number: 20110152290
    Abstract: The present invention relates to compounds of the formula I, wherein A, Y, Z, R3 to R6, R20 to R22 and R50 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. Specifically, they are inhibitors of the endothelial differentiation gene receptor 2 (Edg-2, EDG2), which is activated by lysophosphatidic acid (LPA) and is also termed as LPA1 receptor, and are useful for the treatment of diseases such as atherosclerosis, myocardial infarction and heart failure, for example. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use and pharmaceutical compositions comprising them.
    Type: Application
    Filed: November 4, 2010
    Publication date: June 23, 2011
    Applicant: SANOFI-AVENTIS
    Inventors: Matthias SCHAEFER, Josef PERNERSTORFER, Dieter KADEREIT, Hartmut STROBEL, Werngard CZECHTIZKY, L. Charlie CHEN, Alena SAFAROVA, Aleksandra WEICHSEL, Marcel PATEK
  • Publication number: 20110092539
    Abstract: The present invention relates to a heterocyclic derivative according to formula (I); wherein the variables are defined as in the specification, or to a pharmaceutically acceptable salt or solvate thereof. The present invention also relates to a pharmaceutical composition comprising said heterocyclic derivatives and to their use in therapy, for instance in the treatment or prevention of psychiatric diseases where an enhancement of synaptic responses mediated by AMPA receptors is required, including schizophrenia, depression and Alzheimer's disease.
    Type: Application
    Filed: June 3, 2009
    Publication date: April 21, 2011
    Inventors: Jonathan Gillespie, Craig Jamieson, Zoran Rankovic
  • Patent number: 7902207
    Abstract: A process for producing an amine which is characterized by reacting an imine with a nucleophilic compound (except a trialkylsilyl vinyl ether) in the presence of a phosphoric acid derivative represented by the formula (1): wherein A1 represents a spacer; X1 and X2 represent each independently a divalent nonmetal atom or a divalent nonmetal atomic group; and Y1 is oxygen or sulfur. The invention provides a process by which amines (particularly optically active amines) useful as intermediates of medicines, agricultural chemicals, or the like can be produced without special post-treatment in high yield at high optical purity; and phosphoric acid derivatives (particularly optically active phosphoric acid derivatives) useful in the production of the amines.
    Type: Grant
    Filed: January 26, 2005
    Date of Patent: March 8, 2011
    Assignee: Takasago International Corporation
    Inventors: Masahiro Terada, Daisuke Uraguchi, Keiichi Sorimachi, Hideo Shimizu
  • Publication number: 20100324159
    Abstract: Embodiments of the present invention are directed to porous resins for solid phase extractions. The resins feature at least one hydrophobic component, at least one hydrophilic component and at least one ion exchange functional group. The resins exhibit superior wetting and ion exchange performance.
    Type: Application
    Filed: August 12, 2010
    Publication date: December 23, 2010
    Applicant: Waters Technologies Corporation
    Inventors: Peter Jeng Jong LEE, John E. O'Gara